This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 987 entries already.
The Leukemia & Lymphoma Society (LLS) and Polish drug developer Selvita SA have entered a partnership to co-fund further preclinical and clinical development of a targeted therapy to treat patients […]
Gene therapy specialist Uniqure NV announced new executive appointments to its leadership team and nominations to its Board of Directors. Scott McMillan, for instance, will be responsible for all current […]
Sweden’s Hansa Medical AB presented data showing its experimental drug allowed doctors to perform successful kidney transplants in patients with a particularly high risk of organ rejection.
Johnson & Johnson has entered a new deal with Danish biotech Bavarian Nordic worth up to US$879m to develop vaccine regimens against hepatitis B and HIV.
UKs biggest pharma firm announced it will save an additional £1bn each year by 2020. 80% of the pharmaceutical R&D pipeline expenses will be directed towards two current (Respiratory and […]
Belgian nanobody-developer Ablynx NV now also works together with French pharma company Sanofi. The deal is potentially worth 2.4bn but comes with an upfront payment of just 23m. The partners […]
Venture capitalist Seventure Partners announced that it has participated in a US$13m financing of Japanese biotech company Anaeropharma Science. The investment is made from Seventures Health for Life Capital investment […]